Objective:Ovarian cancer(OC)ranks among the leading causes of mortality among the female cancers worldwide.Numerous studies have explored the development and progression of OC at multiple genetic regulatory levels.How...Objective:Ovarian cancer(OC)ranks among the leading causes of mortality among the female cancers worldwide.Numerous studies have explored the development and progression of OC at multiple genetic regulatory levels.However,relatively few studies have explored the impact of post-translational modifications(PTM)on OC progression,which is essential for uncovering new therapeutic targets.This study aimed to systematically identify the key PTM types involved in OCprogression,and to explore and evaluate their translational potential as therapeutic targets.Methods:First,we utilized multiple general PTM antibodies to compare gross PTM levels between normal ovarian and OC tissues from clinical females.After identifying lactylation as the PTM with the most significant differences,we selected representative samples for label-free mass spectrometry to identify specific lactylation sites.Next,we transfected A2780(OC)cells with either wild-type(WT)or mutant(K192A[Q])poly(ADP-ribose)polymerase 1(PARP1)conjugated to enhanced green fluorescent protein(EGFP)with a StrepⅡpeptide tag and assessed various cellular indexes related to cell proliferation(clonogenicity assay),migration(scratch wound healing assay),and reactive oxygen species levels.Results:Pan-lactylation was significantly upregulated in clinical OC samples,with PARP1 lactylation at K192 being one of the most common modifications.The growth and migration of A2780 cells were markedly suppressed by overexpressing PARP1-WT but not mutant PARP1.Overexpressing PARP1 significantly downregulated the phosphorylation of extracellular signal-regulated kinases 1/2(ERK1/2).Conclusion:This study uncovered a novel PTM of PARP1 in OC,lactylation,and demonstrated that lactylation at K192 is crucial in regulating OC cell growth and migration via the ERK1/2 pathway.Further investigations are required to elucidate the broader functional implications of PARP1 lactylation and its therapeutic potential.展开更多
PARP1和CDK2在癌症发生发展中起关键作用,二者过度活化与多种肿瘤相关,同时抑制二者活性可能为乳腺癌治疗提供有效策略。本文以PARP1抑制剂Olaparib和CDK抑制剂Ribociclib为基础,通过分子对接分析选择分子尾部游离基团作为改造位点,设...PARP1和CDK2在癌症发生发展中起关键作用,二者过度活化与多种肿瘤相关,同时抑制二者活性可能为乳腺癌治疗提供有效策略。本文以PARP1抑制剂Olaparib和CDK抑制剂Ribociclib为基础,通过分子对接分析选择分子尾部游离基团作为改造位点,设计合成了5个具有全新结构的PARP-CDK双靶点抑制剂。利用核磁共振氢谱对其结构进行表征,通过测试酶抑制活性和体外抗细胞增殖活性进行生物活性评价。结果显示,双杂环链接化合物活性优于单杂环化合物,其中链接链为3,9-二氮杂螺[5.5]十一烷的化合物12c对PARP1与CDK2显示出良好的抗肿瘤效果。本研究为开发更多PARP1双靶点抑制剂奠定了重要基础。The proteins PARP1 and CDK2 are pivotal in the progression of cancer, with their excessive activation being implicated in a wide range of tumors. Targeting and simultaneously inhibiting the activities of both PARP1 and CDK2 may hold promise as a highly effective therapeutic strategy for the treatment of breast cancer. In this paper, five PARP-CDK dual-target inhibitors with a novel structure were designed and synthesized based on the PARP1 inhibitor Olaparib and the CDK inhibitor Ribociclib. The molecular docking analysis was used to select the free groups at the molecular tail as the modification sites. The structures of the inhibitors were characterized by nuclear magnetic resonance spectroscopy, and their biological activities were evaluated by testing the enzyme inhibitory activity and in vitro anti-cell proliferation activity. The results showed that the activity of the compounds with double heterocyclic linkers was better than that of the single heterocyclic compounds, and the compound 12c with a 3,9-diazaspiro [5.5] undecane linker exhibited good antitumor effects against both PARP1 and CDK2. This study lays an important foundation for the development of more PARP1 dual-target inhibitors.展开更多
文摘Objective:Ovarian cancer(OC)ranks among the leading causes of mortality among the female cancers worldwide.Numerous studies have explored the development and progression of OC at multiple genetic regulatory levels.However,relatively few studies have explored the impact of post-translational modifications(PTM)on OC progression,which is essential for uncovering new therapeutic targets.This study aimed to systematically identify the key PTM types involved in OCprogression,and to explore and evaluate their translational potential as therapeutic targets.Methods:First,we utilized multiple general PTM antibodies to compare gross PTM levels between normal ovarian and OC tissues from clinical females.After identifying lactylation as the PTM with the most significant differences,we selected representative samples for label-free mass spectrometry to identify specific lactylation sites.Next,we transfected A2780(OC)cells with either wild-type(WT)or mutant(K192A[Q])poly(ADP-ribose)polymerase 1(PARP1)conjugated to enhanced green fluorescent protein(EGFP)with a StrepⅡpeptide tag and assessed various cellular indexes related to cell proliferation(clonogenicity assay),migration(scratch wound healing assay),and reactive oxygen species levels.Results:Pan-lactylation was significantly upregulated in clinical OC samples,with PARP1 lactylation at K192 being one of the most common modifications.The growth and migration of A2780 cells were markedly suppressed by overexpressing PARP1-WT but not mutant PARP1.Overexpressing PARP1 significantly downregulated the phosphorylation of extracellular signal-regulated kinases 1/2(ERK1/2).Conclusion:This study uncovered a novel PTM of PARP1 in OC,lactylation,and demonstrated that lactylation at K192 is crucial in regulating OC cell growth and migration via the ERK1/2 pathway.Further investigations are required to elucidate the broader functional implications of PARP1 lactylation and its therapeutic potential.
文摘PARP1和CDK2在癌症发生发展中起关键作用,二者过度活化与多种肿瘤相关,同时抑制二者活性可能为乳腺癌治疗提供有效策略。本文以PARP1抑制剂Olaparib和CDK抑制剂Ribociclib为基础,通过分子对接分析选择分子尾部游离基团作为改造位点,设计合成了5个具有全新结构的PARP-CDK双靶点抑制剂。利用核磁共振氢谱对其结构进行表征,通过测试酶抑制活性和体外抗细胞增殖活性进行生物活性评价。结果显示,双杂环链接化合物活性优于单杂环化合物,其中链接链为3,9-二氮杂螺[5.5]十一烷的化合物12c对PARP1与CDK2显示出良好的抗肿瘤效果。本研究为开发更多PARP1双靶点抑制剂奠定了重要基础。The proteins PARP1 and CDK2 are pivotal in the progression of cancer, with their excessive activation being implicated in a wide range of tumors. Targeting and simultaneously inhibiting the activities of both PARP1 and CDK2 may hold promise as a highly effective therapeutic strategy for the treatment of breast cancer. In this paper, five PARP-CDK dual-target inhibitors with a novel structure were designed and synthesized based on the PARP1 inhibitor Olaparib and the CDK inhibitor Ribociclib. The molecular docking analysis was used to select the free groups at the molecular tail as the modification sites. The structures of the inhibitors were characterized by nuclear magnetic resonance spectroscopy, and their biological activities were evaluated by testing the enzyme inhibitory activity and in vitro anti-cell proliferation activity. The results showed that the activity of the compounds with double heterocyclic linkers was better than that of the single heterocyclic compounds, and the compound 12c with a 3,9-diazaspiro [5.5] undecane linker exhibited good antitumor effects against both PARP1 and CDK2. This study lays an important foundation for the development of more PARP1 dual-target inhibitors.
